Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-2505
- Development stage
- Preclinical
- Lead developer
- Indivumed
01
Overview
IN-2505 is a preclinical biologic therapeutic currently under development by Indivumed for the treatment of colorectal cancer (CRC). Identified through Indivumed's proprietary multi-omics platform and patient-derived datasets, the drug is designed to address novel targets in the CRC landscape. As of September 2025, the program is in the 'Hit to Lead' stage of development. While the specific molecular target remains proprietary and undisclosed, the development of IN-2505 represents part of Indivumed's broader strategy to leverage high-quality clinical data for the discovery of precision oncology treatments.
Beyond the preview
Go deeper on IN-2505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-2505.